Advances in plant-based inhibitors of P-glycoprotein

References

• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58
   PubMed Web of Science ®Google Scholar
• Romiti A, Cox MC, Sarcina I, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 2013;72:13–33
   PubMed Web of Science ®Google Scholar
• Colabufo NA, Pagliarulo V, Berardi F, et al. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins. Eur J Pharmacol 2008;601:38–42
   PubMed Web of Science ®Google Scholar
• Elkadi OA. MDR-selective microbial-based therapy: a novel approach to cancer treatment. Med Hypotheses 2013;81:207–11
   PubMed Web of Science ®Google Scholar
• Huang Y, Sadee W. Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. Drug Discov Today 2003;8:356–63
   PubMed Web of Science ®Google Scholar
• Montazami N, Aghapour M, Farajnia S, et al. New insights into the mechanisms of multidrug resistance in cancers. Cell Mol Biol (Noisy-le-grand) Mol 2015;61:70–80
   PubMed Web of Science ®Google Scholar
• Gatouillat G, Magid AA, Bertin E, et al. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells. Phytomedicine 2015;22:1186–94
   PubMed Web of Science ®Google Scholar
• Ji M, Shi Y, Lou H, et al. Overcoming of P-glycoprotein-mediated multidrug resistance in K562/A02 cells using riccardin F and pakyonol, bisbibenzyl derivatives from liverworts. Biosci Trends 2011;5:192–7
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216–37
   PubMed Web of Science ®Google Scholar
• Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974;83:103–16
   PubMed Web of Science ®Google Scholar
• Schinkel AH1, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3–29
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 2006;580:998–1009
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012;19:1946–2025
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Vural I, Levchenko T, et al. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. Drug Deliv 2012;19:169–76
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967–72
   PubMed Web of Science ®Google Scholar
• Safa AR. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 1988;85:7187–91
   PubMed Web of Science ®Google Scholar
• Shiraga K, Sakaguchi K, Senoh T, et al. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin-resistant sublines. J Gastroenterol Hepatol 2001;16:460–6
   PubMed Web of Science ®Google Scholar
• Angelini A, Iezzi M, Di Febbo C, et al. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 2008;20:731–5
   PubMed Web of Science ®Google Scholar
• Pearce HL, Safa AR, Bach NJ, et al. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 1989;86:5128–32
   PubMed Web of Science ®Google Scholar
• Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 2004;32:20–7
   PubMed Web of Science ®Google Scholar
• Liu ZH, Ma YL, He YP, et al. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep 2011;38:1769–75
   PubMed Web of Science ®Google Scholar
• Palmeira A, Rodrigues F, Sousa E, et al. New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des 2011;78:57–72
   PubMed Web of Science ®Google Scholar
• Bark H, Choi CH. PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB. Cancer Chemother Pharmacol 2010;65:1131–6
   PubMed Web of Science ®Google Scholar
• Bates SF, Chen C, Robey R, et al. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002;243:83–96; discussion 96–102, 180–5
   PubMedGoogle Scholar
• Biscardi M, Teodori E, Caporale R, et al. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk Res 2006;30:1–8
   PubMed Web of Science ®Google Scholar
• Lee SY, Rhee YH, Jeong SJ, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol 2011;26:424–31
   PubMed Web of Science ®Google Scholar
• Pire MM, Emmert D, Hrycyna CA, et al. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol 2009;75:92–100
   PubMed Web of Science ®Google Scholar
• Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749–58
   PubMed Web of Science ®Google Scholar
• Marcelletti JF, Multani PS, Lancet JE, et al. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res 2009;33:769–74
   PubMed Web of Science ®Google Scholar
• Kuntner C, Bankstahl JP, Bankstahl M, et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging 2010;37:942–53
   PubMed Web of Science ®Google Scholar
• Lee BD, French KJ, Zhuang Y, et al. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res 2003;14:49–60
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104:682–91
   PubMed Web of Science ®Google Scholar
• Girdhani S, Bhosle SM, Thulsidas SA, et al. Potential of radiosensitizing agents in cancer chemo-radiotherapy. J Cancer Res Ther 2005;1:129–31
   PubMedGoogle Scholar
• Abdallah HM, Al-Abd AM, El-Dine RS, et al. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J Adv Res 2015;6:45–62
   PubMed Web of Science ®Google Scholar
• Anthony V, Skach WR. Molecular mechanism of P-glycoprotein assembly into cellular membranes. Curr Protein Pept Sci 2002;3:485–501
   PubMed Web of Science ®Google Scholar
• Sun J, He ZG, Cheng G, et al. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 2004;10:RA5–14
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468–85
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 2005;206:173–85
   PubMed Web of Science ®Google Scholar
• Ferté J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 2000;267:277–94
   PubMedGoogle Scholar
• Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 1996;33:533–41
   PubMed Web of Science ®Google Scholar
• Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest 2013;123:4131–3
   PubMed Web of Science ®Google Scholar
• Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med 2015;29:1–6
   PubMed Web of Science ®Google Scholar
• Tucker TG, Milne AM, Fournel-Gigleux S, et al. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol 2012;83:279–85
   PubMed Web of Science ®Google Scholar
• Tang YZ, Li DQ, Sun FJ, et al. P-glycoprotein regulating biphasic insulin secretion in rat pancreatic beta cells. Chin Med J (Engl) 2009;122:2587–92
   PubMed Web of Science ®Google Scholar
• Water FM, Boleij JM, Peters JG, et al. Characterization of P-glycoprotein and multidrug resistance proteins in rat kidney and intestinal cell lines. Eur J Pharm Sci 2007;30:36–44
   PubMed Web of Science ®Google Scholar
• Ellis K, Marlin JW, Taylor TA, et al. The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model. J Pharm Pharmacol 2015;67:178–88
   PubMed Web of Science ®Google Scholar
• Johnson WW. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 2002;24:501–14
   PubMedGoogle Scholar
• Huang L, Li X, Roberts J, et al. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats. Xenobiotica 2015;45:547–55
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59–98
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Smith MM, Müller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481–91
   PubMed Web of Science ®Google Scholar
• Sharom FJ. Complex Interplay between the P-Glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol 2014;4:41
   PubMedGoogle Scholar
• Callaghan R, Ford RC, Kerr ID. The translocation mechanism of P-glycoprotein. FEBS Lett 2006;580:1056–63
   PubMed Web of Science ®Google Scholar
• Orelle C, Gubellini F, Durand A, et al. Conformational change induced by ATP binding in the multidrug ATP-binding cassette transporter BmrA. Biochemistry 2008;47:2404–12
   PubMed Web of Science ®Google Scholar
• García-Carrasco M, Mendoza-Pinto C, Macias Díaz S, et al. P-glycoprotein in autoimmune rheumatic diseases. Autoimmun Rev 2015;14:594–600
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011;50:161–78
   PubMed Web of Science ®Google Scholar
• Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013;7:27–34
   PubMedGoogle Scholar
• Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347–59
   PubMed Web of Science ®Google Scholar
• Srivalli KMR, Lakshmi PK. Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharm Sci 2012;48:353–67
   Web of Science ®Google Scholar
• Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 1998;333:351–8
   PubMed Web of Science ®Google Scholar
• Ramachandra M, Ambudkar SV, Gottesman MM, et al. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell 1996;7:1485–98
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006;27:392–400
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997;53:587–96
   PubMed Web of Science ®Google Scholar
• Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991–2002
   PubMed Web of Science ®Google Scholar
• Nijveldt RJ, van Nood E, van Hoorn DE, et al. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74:418–25
   PubMed Web of Science ®Google Scholar
• Narayana KR, Reddy MS, Chaluvadi MR, et al. Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Ind. J Pharmacol 2001;33:2–16
   Google Scholar
• Boumendjel A, Di Pietro A, Dumontet C, et al. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 2002;22:512–29
   PubMed Web of Science ®Google Scholar
• Chieli E, Romiti N, Catiana Zampini I, et al. Effects of Zuccagnia punctata extracts and their flavonoids on the function and expression of ABCB1/P-glycoprotein multidrug transporter. J Ethnopharmacol 2012;144:797–801
   PubMed Web of Science ®Google Scholar
• Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005;17:86–95
   PubMed Web of Science ®Google Scholar
• Yu CP, Wu PP, Hou YC, et al. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric Food Chem 2011;59:4644–8
   PubMed Web of Science ®Google Scholar
• Castro AF, Altenberg GA. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 1997;53:89–93
   PubMed Web of Science ®Google Scholar
• Sun L, Chen W, Qu L, et al. Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression. Mol Med Rep 2013;8:1883–7
   PubMed Web of Science ®Google Scholar
• Li C, Kim M, Choi H, Choi J. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res 2011;34:1965–72
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;304:1258–67
   PubMed Web of Science ®Google Scholar
• Lee E, Enomoto R, Koshiba C, et al. Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. Ann N Y Acad Sci 2009;1171:132–6
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 1995;270:16167–75
   PubMed Web of Science ®Google Scholar
• Zhang X, Song J, Shi X, et al. Absorption and metabolism characteristics of rutin in Caco-2 cells. Scientific World J 2013;10:382350
   Google Scholar
• Floyd KA, Stella DR, Wang CC, et al. Genistein and genistein-containing dietary supplements accelerate the early stages of cataractogenesis in the male ICR/f rat. Exp Eye Res 2011;92:120–7
   PubMed Web of Science ®Google Scholar
• Nakatsuma A, Fukami T, Suzuki T, et al. Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G. Pharmazie 2010;65:379–83
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003;20:1184–91
   PubMed Web of Science ®Google Scholar
• Pick A, Muller H, Mayer R, et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 2011;19:2090–102
   PubMed Web of Science ®Google Scholar
• Srinivas NR. Recent trends in preclinical drug-drug interaction studies of flavonoids -Review of case studies, issues and perspectives. Phytother Res 2015;29:1679–91
   PubMed Web of Science ®Google Scholar
• Ma Y, Zeng M, Sun R, et al. Disposition of flavonoids impacts their efficacy and safety. Curr Drug Metab 2014;15:841–64
   PubMed Web of Science ®Google Scholar
• Actis-Goretta L, Lévèques A, Rein M, et al. Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J Clin Nutr 2013;98:924–33
   PubMed Web of Science ®Google Scholar
• Yang Z, Kulkarni K, Zhu W, et al. Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem 2012;12:1264–80
   PubMed Web of Science ®Google Scholar
• Qiu S, Sun H, Zhang AH, et al. Natural alkaloids: basic aspects, biological roles, and future perspectives. Chin J Nat Med 2014;12:401–6
   PubMed Web of Science ®Google Scholar
• Lei Y, Tan J, Wink M, et al. An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1. Food Chem 2013;136:1117–21
   PubMed Web of Science ®Google Scholar
• Ma Y, Wink M. Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine 2008;15:754–8
   PubMed Web of Science ®Google Scholar
• Chavez D, Cui B, Chai HB, et al. Reversal of multidrug resistance by tropane alkaloids from the stems of Erythroxylum rotundifolium. J Nat Prod 2002;65:606–10
   PubMed Web of Science ®Google Scholar
• Ikeda R, Che XF, Yamaguchi T, et al. Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci 2005;96:372–6
   PubMed Web of Science ®Google Scholar
• Wang YH, Goto M, Wang LT, et al. Multidrug resistance-selective antiproliferative activity of Piper amide alkaloids and synthetic analogues. Bioorg Med Chem Lett 2014;24:4818–21
   PubMed Web of Science ®Google Scholar
• Choi SU, Park SH, Kim KH, et al. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs 1998;9:255–61
   PubMed Web of Science ®Google Scholar
• Arora A, Seth K, Kalra N, et al. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Toxicol Appl Pharmacol 2005;202:237–43
   PubMed Web of Science ®Google Scholar
• Mi Q, Cui B, Silva GL, et al. Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay. Cancer Lett 2002;184:13–20
   PubMed Web of Science ®Google Scholar
• Chanmahasathien W, Ohnuma S, Ambudkar SV, et al. Biochemical mechanism of modulation of human P-glycoprotein by stemofoline. Planta Med 2011;77:1990–5
   PubMed Web of Science ®Google Scholar
• Shiraishi N, Akiyama S, Nakagawa M, et al. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res 1987;47:2413–16
   PubMed Web of Science ®Google Scholar
• Weiss J, Sauer A, Frank A, et al. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos 2005;33:1580–3
   PubMed Web of Science ®Google Scholar
• Sun YF, Wink M. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine 2014;21:1110–19
   PubMed Web of Science ®Google Scholar
• Chanmahasathien W, Ampasavate C, Greger H, et al. Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance. Phytomedicine 2011;18:199–204
   PubMed Web of Science ®Google Scholar
• Egan D, O’Kennedy R, Moran E, et al. The pharmacology, metabolism, analysis and applications of coumarin and coumarin-related compounds. Drug Metab Rev 1990;22:503–29
   PubMed Web of Science ®Google Scholar
• Lacy A, O'Kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 2004;10:3797–811
   PubMed Web of Science ®Google Scholar
• Raad I, Terreux R, Richomme P, et al. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. Bioorg Med Chem 2006;14:6979–87
   PubMed Web of Science ®Google Scholar
• Barthomeuf C, Demeule M, Grassi J, et al. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport. Planta Med 2006;72:634–9
   PubMed Web of Science ®Google Scholar
• Barthomeuf C, Grassi J, Demeule M, et al. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 2005;56:173–81
   PubMed Web of Science ®Google Scholar
• Bayet C, Fazio C, Darbour N, et al. Modulation of P-glycoprotein activity by acridones and coumarins from Citrus sinensis. Phytother Res 2007;21:386–90
   PubMed Web of Science ®Google Scholar
• Madureira AM, Molnar A, Abreu PM, et al. A new sesquiterpene-coumarin ether and a new abietane diterpene and their effects as inhibitors of P-glycoprotein. Planta Med 2004;70:828–33
   PubMed Web of Science ®Google Scholar
• Hanafi-Bojd MY, Iranshahi M, Mosaffa F, et al. Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines. Planta Med 2011;77:1590–3
   PubMed Web of Science ®Google Scholar
• Kimura S, Ito C, Jyoko N, et al. Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from Calophyllum brasiliense that acts by induction of apoptosis. Int J Cancer 2005;113:158–65
   PubMed Web of Science ®Google Scholar
• Jabeen I, Wetwitayaklung P, Chiba P, et al. 2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein. J Comput Aided Mol Des 2013;27:161–71
   PubMed Web of Science ®Google Scholar
• Hoult JR, Payá M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol 1996;27:713–22
   PubMedGoogle Scholar
• Dewick PM. The biosynthesis of C5-C25 terpenoid compounds. Nat Prod Rep 2002;19:181–222
   PubMed Web of Science ®Google Scholar
• Yoshida N, Koizumi M, Adachi I, et al. Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products. Food Chem Toxicol 2006;44:2033–9
   PubMed Web of Science ®Google Scholar
• Appendino G, Jakupovic S, Tron GC, et al. Macrocyclic diterpenoids from Euphorbia semiperfoliata. J Nat Prod 1998;61:749–56
   PubMed Web of Science ®Google Scholar
• Valente I, Reis M, Duarte N, et al. Jatrophane diterpenes from Euphorbia mellifera and their activity as P-glycoprotein modulators on multidrug-resistant mouse lymphoma and human colon adenocarcinoma cells. J Nat Prod 2012;75:1915–21
   PubMed Web of Science ®Google Scholar
• Appendino G, Della Porta C, Conseil G, et al. A new P-glycoprotein inhibitor from the caper spurge (Euphorbia lathyris). J Nat Prod 2003;66:140–2
   PubMed Web of Science ®Google Scholar
• Madureira AM, Gyemant N, Ascenso JR, et al. Euphoportlandols A and B, tetracylic diterpene polyesters from Euphorbia portlandica and their anti-MDR effects in cancer cells. J Nat Prod 2006;69:950–3
   PubMed Web of Science ®Google Scholar
• Min YD, Kwon HC, Yang MC, et al. Isolation of limonoids and alkaloids from Phellodendron amurense and their multidrug resistance (MDR) reversal activity. Arch Pharm Res 2007;30:58–63
   PubMed Web of Science ®Google Scholar
• Lota ML, de Rocca Serra D, Tomi F, et al. Volatile components of peel and leaf oils of lemon and lime species. J Agric Food Chem 2002;50:796–805
   PubMed Web of Science ®Google Scholar
• Kawakami J, Yamamura Y, Santa T, et al. Kinetic analysis of glycyrrhetic acid, an active metabolite of glycyrrhizin, in rats: role of enterohepatic circulation. J Pharm Sci 1993;82:301–5
   PubMed Web of Science ®Google Scholar
• Reyes CP, Munoz-Martinez F, Torrecillas IR, et al. Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance. J Med Chem 2007;50:4808–17
   PubMed Web of Science ®Google Scholar
• Molnar J, Gyemant N, Tanaka M, et al. Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr Pharm Des 2006;12:287–311
   PubMed Web of Science ®Google Scholar
• Fang S, Hao C, Sun W, et al. Rapid analysis of steroidal saponin mixture using electrospray ionization mass spectrometry combined with sequential tandem mass spectrometry. Rapid Commun Mass Spectrom Commun 1998;12:589–94
   PubMed Web of Science ®Google Scholar
• Yang Y, Laval S, Yu B. Chemical synthesis of saponins. Adv Carbohydr Chem Biochem 2014;71:137–226
   PubMed Web of Science ®Google Scholar
• D'Uva G, Lauriola M. Towards the emerging crosstalk: ERBB family and steroid hormones. Semin Cell Dev Biol 2015;12:250–5
   Google Scholar
• Li Y, Fan L, Sun Y, et al. Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation. J Ethnopharmacol 2014;154:728–34
   PubMed Web of Science ®Google Scholar
• Kim SW, Kwon HY, Chi DW, et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 2003;65:75–82
   PubMed Web of Science ®Google Scholar
• Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 2003;69:235–40
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Darbour N, Bayet C, et al. Selective modulation of P-glycoprotein activity by steroidal saponines from Paris polyphylla. Fitoterapia 2009;80:39–42
   PubMed Web of Science ®Google Scholar
• Sun H, Yang Z, Ye Y. Structure and biological activity of protopanaxatriol-type saponins from the roots of Panax notoginseng. Int Immunopharmacol 2006;6:14–25
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Zhu Z, et al. Exploration of the correlation between the structure, hemolytic activity, and cytotoxicity of steroid saponins. Bioorg Med Chem 2007;15:2528–32
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J 2006;399:351–9
   PubMed Web of Science ®Google Scholar
• Tan W, Mei H, Chao L, et al. Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors. J Comput Aided Mol Des 2013;27:1067–73
   PubMed Web of Science ®Google Scholar
• Kim KH. 3D-QSAR analysis of 2,4,5- and 2,3,4,5-substituted imidazoles as potent and nontoxic modulators of P-glycoprotein mediated MDR. Bioorg Med Chem 2001;9:1517–23
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. Curr Pharm Des 2012;18:4197–214
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J Biol Chem 2000;275:39272–8
   PubMed Web of Science ®Google Scholar